A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

Summary

After receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1, experimental group 2 and the control group in this Phase IIa clinical trial. The study will be followed up until 24 to 36 months after treatment.

Timeline

Start

2026-02-26

Primary completion

2027-12-31

Completion

2028-12-31

Drugs

Indications